Abstract 49P
Background
To date, miR-155 is known as an oncogenic miRNA with a well-documented role in breast cancer. Cancer stemness plays an important role in various aspects of carcinogenesis. The aim of this study is to investigate the effect of miR-155 on breast cancer proliferation by upregulating cancer stem cells.
Methods
In vivo-tumor growth and metastasis were measured across polyomavirus middle T antigen (PyVmT) transgenic mice and PyVmT miR-155 knockout mice. Western blot and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to determine the protein and mRNA levels, respectively. The cancer stemness was assessed by sphere formation as well as the expression of the related markers. The miR-155 target genes were predicted and analyzed by western blot and luciferase assay.
Results
Upregulation of miR-155 in breast cancer tissues of mice identified poor prognosis and cancer metastasis. Upregulation of miR-155 was also found in breast cancer stem cells. Ectopic expression of miR-155 promotes the stemness of breast cancer cells. Conversely, depletion of miR-155 attenuates the stemness of these cells. miR-155 directly binds to CYLD and Sharp-1 to influence breast cancer stemness.
Conclusions
MicroRNA-155 promotes breast cancer progression by upregulating breast cancer stemness.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract